Dyslipidemia in patients with nonalcoholic fatty liver disease.
about
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individualsA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDObesity Disease and SurgeryPerspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future TherapiesThe association of nonalcoholic fatty liver disease with central and peripheral blood pressure in adolescence: findings from a cross-sectional study.Nonalcoholic fatty liver disease and cardiovascular diseaseTriglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes.Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liverIdentification of novel clinical factors associated with hepatic fat accumulation in extreme obesity.Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese populationOmega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase.Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.Managing the combination of nonalcoholic Fatty liver disease and metabolic syndrome with chinese herbal extracts in high-fat-diet fed rats.Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease.High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice.Mitochondrial DNA 5178 C/A polymorphism modulates the effects of coffee consumption on elevated levels of serum liver enzymes in male Japanese health check-up examinees: an exploratory cross-sectional study.Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity.Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.Clinical approaches to non-alcoholic fatty liver diseaseLipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences.Emerging drugs for non-alcoholic steatohepatitis.Coumarin attenuates hepatic steatosis by down-regulating lipogenic gene expression in mice fed a high-fat diet.Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia.Therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced fatty liver disease, fibrosis and inflammation in rabbit.Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression.Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease.SCAP gene polymorphisms decrease the risk of nonalcoholic fatty liver disease in females with metabolic syndrome.Assessment of endothelial function in patients with nonalcoholic fatty liver disease.Prediction of prevalent but not incident non-alcoholic fatty liver disease by levels of serum testosterone.Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases.Lingguizhugan decoction improves non-alcoholic fatty liver disease by altering insulin resistance and lipid metabolism related genes: a whole trancriptome study by RNA-Seq.Dietary α-lactalbumin induced fatty liver by enhancing nuclear liver X receptor αβ/sterol regulatory element-binding protein-1c/PPARγ expression and minimising PPARα/carnitine palmitoyltransferase-1 expression and AMP-activated protein kinase α phosPilose antler peptide attenuates high-fat-diet-induced liver injury.Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats.Myricetin derived from Hovenia dulcis Thunb. ameliorates vascular endothelial dysfunction and liver injury in high choline-fed mice.NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects.Fat and carbohydrate content in the diet induces drastic changes in gene expression in young Göttingen minipigs.Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).
P2860
Q22299426-C5AF5DD2-5C1D-4408-B768-6FC6C5B7E017Q26752487-3802A55E-B9DD-460A-8B4E-53F80389FAAAQ26822547-D3ECE6C5-3541-48CD-8265-9C861E067CE5Q30234444-FFC010B9-78AB-48A9-976A-A1A9C5B8894DQ30418630-B9C208EF-21F8-4954-8FD1-78A19DA97901Q33886952-A3209F9E-06B1-400C-A5CE-DF71D1DFFB0EQ33932461-125B64D8-7CF1-43E3-81C7-2D4823E2275EQ33962221-CB31BD14-0143-4EC3-A2E1-E8F49B478CB1Q34907809-37AFA8CA-DE10-4ED1-B412-7A8605983225Q36120514-19CF6249-FDB3-4236-ABA9-3DDB03AB9F38Q36164661-647BF492-DAF3-4D5D-ADA6-D6DB4476D66BQ36606873-444E7C56-C592-4D6C-84F6-6D53239986F4Q36657068-CE3956C9-BCE2-48D3-8150-73F134BF0AE1Q36905761-4611D65F-0541-466D-9E92-6743689C8633Q36937909-1D780566-DB1A-46BB-9934-5A73E71DCC7AQ36969113-D5A4F3F6-D452-4E61-9014-8BCC7C718E29Q37394350-4A57F539-E60C-4D10-A9DC-782A7158932DQ37465565-B05159FB-689F-457F-8BB6-FC7676C44DEDQ37596187-25B7C1DC-5D3D-42F3-BEAF-636AA28DB919Q37705810-8708E5FE-9540-4ADC-AED8-5E60473A4F9AQ38052857-251452ED-0169-48F0-A496-098BC8AEA120Q38121137-889C0FDB-79E1-4493-BEF3-448063A3095DQ38316232-99A9F1AD-E78C-4161-8B1A-B25E51B07BCEQ38588541-B913E477-1CE3-4A7C-AE30-5F9917F91D3AQ38680250-71199601-1ABB-4B0E-96E7-A2E2977E8191Q41549432-AD10057F-7473-47FB-8E8C-2AEBD0A00880Q41849677-F40E459E-1227-4CE0-A9CF-76343A11C4D5Q41986990-D684F282-6C19-4815-BD48-61F0D5DC7ED3Q43593551-078523EC-2D0D-4739-B091-DF92D557C418Q43663978-1DF10CAD-0EAB-4220-B762-A3E396093521Q45224333-7E8BD270-DC4B-4325-90AB-77DE87D0235BQ47156332-9A56ADF7-6A46-4D05-9841-6542B525CF88Q47175346-715A6399-61A4-4ED1-ACA7-F0665B138790Q47367132-FF7A1B7A-1FC7-42CD-8A68-BF008F5BE508Q47424206-FAC31907-AD01-4CAB-A645-DAB6D3482AB7Q49810183-01382911-A8CD-4B4E-AAED-E0E284BA6BA6Q50447912-B3A37106-7329-4E4D-946C-AD99EBEAF0ECQ52323790-999D8659-7BB0-40F1-A691-E0161030B88CQ53365082-C284B18F-5413-4382-AEA0-74848D41A275Q55266683-ED6AC818-0D29-4564-9720-06DFC29F2015
P2860
Dyslipidemia in patients with nonalcoholic fatty liver disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dyslipidemia in patients with nonalcoholic fatty liver disease.
@en
type
label
Dyslipidemia in patients with nonalcoholic fatty liver disease.
@en
prefLabel
Dyslipidemia in patients with nonalcoholic fatty liver disease.
@en
P2860
P356
P1476
Dyslipidemia in patients with nonalcoholic fatty liver disease
@en
P2093
Hemant Chatrath
Naga Chalasani
P2860
P356
10.1055/S-0032-1306423
P577
2012-02-01T00:00:00Z